Findoc-cll.in/3rd_qtr_result

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED RESULTS FOR THE QUARTER ENDED : 31ST DECEMBER 2012.

(Rupees in '000')

S. No.

Particulars

Un -audited

Un-audited

Audited

Quarter Ended

Nine Month Ended

Year

31.Dec.12

30.Sep.12

31.Dec.11

31.Dec.12

31.Dec.11

31.Mar.12

PART-l

(a)Income from Operation

Gross Sales

16,927

19,157

17,496

59,338

57,230

70,455

less Excise Duty

1,191

1,264

1,000

4,003

2,926

4,435

Net Sales/Income From Operation

15,736

17,893

16,496

55,335

54,304

66,020

(b) Other Operating Income

323

Total Income from Operation

16,059

17,893

16,496

55,658

54,304

66,020

Expenses

(a)

Cost Of Material Consumed

5,178

7,088

4,587

18,249

17,656

24,418

(b)

Purchase of Stock in Trade

942

1,504

483

4,316

2,521

3,457

(c)

Change in Inventories Of Finished Goods and Work in Progress of Stock in trade

(897)

(2,224)

1,473

(732)

3,926

(1,095)

(d)

Employee Benefit Expenses

6,709

6,592

6,313

20,182

17,934

22,545

(e)

Depreciation & Amortisation Expenses

653

644

1,960

1,933

2,599

(f)

Other Expenses

2,905

3,509

2,329

9,527

8,417

11,694

Total Expenses

15,490

17,122

15,829

53,502

52,387

63,618

Profit/(Loss) from Operation Before Other Income ( 1-2)

569

771

667

2,156

1,917

2,402

Other Income

248

508

209

369

Profit /(Loss) from ordinary activities before

622

1,019

722

2,664

2,126

2,771

finance cost & Exception items ( 3+4)

Finance Cost

474

542

526

1,553

1,324

1,893

Profit /(Loss) from ordinary activities after finance Cost but before Exceptional items ( 5-6)

148

477

196

1,111

802

878

Exceptional items

158

Profit /(Loss) from ordinary activities before Tax ( 7-8)

148

477

196

1,111

802

878

Tax Expenses ( Provision for Taxation ) Current tax

158

Deffered tax

(384)

Net Profit/(Loss) From Ordinary Activities after Tax (9-10)

148

477

196

1,111

802

1,104

Paid up Equity Share Capital ( Face Value 10/- Per Share ) [Net of allotment money in arrears]

354,35

Reserves Excluding Revaluation Reserves

7,630

Earning per share (EPS) before extraordinary item( not Annualised)

i) Basic & Diluted

0.24

ii) Diluted

PART-ll

PARTICULARS OF SHAREHOLDING

Public shareholding

Number of Shares

2,904,901

3,080,150

2,904,901

3,080,150

2,902,900

Percentage of shareholding

63.55%

67.38%

63.55%

67.38%

63.51%

Promoters and promoter group Shareholding

Pledged/Encumbered

Number of shares

Percentage of shares (as a % of the total shareholding of promoter and promoter group)

iii

Percentage of shares (as a% of the total share capital of the company)

Non-encumbered

Number of Shares

1,666,099

1,490,850

1,666,099

1,490,850

1,668,100

Percentage of shares (as a% of the total shareholding of promoter and promoter group)

36.45%

32.62%

36.45%

32.62%

36.49%

Percentage of shares (as a % of the total share capital of the company)

100%

B.	INVESTORS COMPLAINTS	3 Months ended 31.12.2012
	Pending at Begining of the Quarter	NIL
	Received During the Quarter	NIL
	Disposed of During the Quarter	NIL
	Remaining at the end of the Quarter	NIL

NOTES :-

The above financial results have been taken on record at a meeting of Board of Directors held on 31-01-2013
The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
Previous period figures have been regrouped wherever required.